What is Tesamorelin?
Tesamorelin is an injecting drug on the market called Egrifta ™ in the United States, which is administered to reduce excess abdominal fat in HIV positive people with lipodystrophy. Also known as the Th907, it is a factor releasing synthetic growth hormone (GHRF). GHRF causes growth hormone production in the body that helps to control the shape of the body, energy consumption and metabolism. This injection was approved by the United States of Food and Drug Administration (FDA) in November 2010 and was available in the US in 2011. Tesamorelin is not indicated for use in children or as a weight loss medicine.
The FDA approved tesamorelin as a treatment of lipodystrophy for HIV-positive patients on November 10, 2010. Lipodystrophy associated with HIV causes metabolic changes in the body that lead to a change in body fat. As a result, patients with lipodystrophy usually accumulate excess fat around their abdominal organs such as the stomach and the liver while losing fat into the face, buttocks, arms and legs.
ExistenceIt provides evidence that indicates that lipodystrophy can only be triggered by HIV infections with only or antiretroviral drugs that patients take. The accumulation of excess fat itself is not harmful, but can contribute to other health problems such as pain, muscle tension and difficult breathing. In addition, patients may worry that their changed physical appearance will alert others to their HIV condition.
This medicine is a synthetic GHRF. It stimulates the production of growth hormones by linking to receptors on front pituitary gland. These growth hormones affect metabolism and body shape. Tesamorelin focuses specifically on the accumulation of fat in the abdominal area. Because this medicine releases growth hormones, patients with active cancer should not take it.
The recommended dose of tesamorelin is one daily 2-till subcutaneous injection. Medicado of the abdomen is usually injected. Instead of injection should turn and avoid the markers, pUPKU and bruises.
Before the FDA approval, clinical trials were performed in HIV patients who had some fat accumulation and whose antiviral therapy was stable. Three studies of 816 patients have shown that daily treatment has reduced abdominal fat after 26 weeks. Most patients experienced a reduction in approximately 18 percent. Once patients stopped treatment, abdominal fat began to accumulate again.
Tesamorelin did not show proof of the interaction of the drug with any of the antiretroviral drugs HIV. Common side effects include mild joint pain and stiffness, mild swelling and stiffness in hands and feet. These problems usually decrease with some fine exercises that release the joints. The redness and tenderness of the injection site were also observed, but usually clearly clear. This drug has caused diabetic symptoms in some patients and antibodies that cause tesamorelin over time to less effective over time.
patients should be over their doctors upcoming medicines, vitamins and supplements that Berou before starting treatment. Diabetic patients are likely to be carefully monitored when taking this drug. Pregnant women or women who become pregnant in the use of tesamorelin should be informed of the potentially dangerous effects of the drug on unborn children.